6th Annual CAR-TCR Summit Europe
Cell and gene therapy (CGT), including chimeric antigen receptor (CAR) T-cell therapy represents a new frontier in the fight against rare genetic disorders and cancers.
Des conceptions d'études complexes, des populations de patients complexes et des exigences de prestations opérationnelles distinctes constituent la norme des essais cliniques de la TCG. New treatment approaches are often unfamiliar to investigators, site staff and patients.
The Syneos Health Cell and Gene Therapy Development Engine, built upon nearly two decades of experience in the field, is the hub for our knowledge and experience in CGT preclinical/clinical development and commercialization, including CAR-T trials. It brings together the cross-functional capabilities needed to navigate the challenges unique to cell therapy trials, accelerate their development and deliver on their promise.
Meet with us at the 6th Annual CAR-TRC Summit to discuss your CAR-T development or commercialization challenge.
Featured Presentation
Understanding the value in patient perceived experience and tolerance in CAR-T treatment
Wednesday, February 22: 5:30 p.m.
Anthony (AJ) Messina, Ph.D.(c), MSHS, CCRP, Director, Assessment & Insight, Insights Gathering, Syneos Health
Vous voulez en savoir plus? Explore Insights Hub
or click on the resources below:
Insights Gathering Patient Voice CAR-T Syneos Health
Additional Details
Listening to the Patient Voice
Illingworth Off-Site Research Nursing
